CAC
IOVA icon

Cowen and Company’s Iovance Biotherapeutics IOVA Stock Holding History

Cowen and Company’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-35,000
Closed -$71K – 709
2021
Q3 		$71K Buy
+35,000
New +$825K ﹤0.01% 356
2020
Q2 		– Sell
-55,800
Closed -$370K – 431
2020
Q1 		$370K Buy
+55,800
New +$1.48M 0.09% 143

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cowen and Company's IOVA Position: Q4 2021 in Review

Cowen and Company sold out of Iovance Biotherapeutics (IOVA) in Q4 2021, closing a stake of 24,491 shares — an estimated $604K sold.

Cowen and Company first reported a position in IOVA in Q1 2020 and held it in 2 quarters. The position peaked at $2.8M in Q1 2020. 246 funds tracked by Wall St. Rank hold IOVA as of Q4 2021.

  • Cowen and Company reported no remaining Iovance Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Cowen and Company sold 24,491 Iovance Biotherapeutics shares in Q4 2021, an estimated $604K.
  • Cowen and Company first reported a position in Iovance Biotherapeutics in Q1 2020 and held it in 2 quarters.
  • Cowen and Company's Iovance Biotherapeutics position peaked at $2.8M in Q1 2020.
  • 246 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2021.

Based on Cowen and Company's 13F filing for Q4 2021, filed 14 Feb 2022.